The DOI matches its Crossref record.
Constitutive Protease-activated Receptor-2-mediated Migration of MDA MB-231 Breast Cancer Cells Requires Both β-Arrestin-1 and -2
Open accessAbstract
Protease-activated receptor-2 (PAR-2) is activated by trypsin-like serine proteases and can promote cell migration through an ERK1/2-dependent pathway, involving formation of a scaffolding complex at the leading edge of the cell. Previous studies also showed that expression of a dominant negative fragment of beta-arrestin-1 reduces PAR-2-stimulated internalization, ERK1/2 activation, and cell migration; however, this reagent may block association of many proteins, including beta-arrestin-2 with clathrin-coated pits. Here we investigate the role of PAR-2 in the constitutive migration of a metastatic breast cancer cell line, MDA MB-231, and use small interfering RNA to determine the contribution of each beta-arrestin to this process. We demonstrate that a trypsin-like protease secreted from MDA MB-231 cells can promote cell migration through autocrine activation of PAR-2 and this correlates with constitutive localization of PAR-2, beta-arrestin-2, and activated ERK1/2 to pseudopodia. Addition of MEK-1 inhibitors, trypsin inhibitors, a scrambled PAR-2 peptide, and silencing of beta-arrestins with small interfering RNA also reduce base-line migration of MDA MB-231 cells. In contrast, a less metastatic PAR-2 expressing breast cancer cell line does not exhibit constitutive migration, pseudopodia formation, or trypsin secretion; in these cells PAR-2 is more uniformly distributed around the cell periphery. These data demonstrate a requirement for both beta-arrestins in PAR-2-mediated motility and suggest that autocrine activation of PAR-2 by secreted proteases may contribute to the migration of metastatic tumor cells through beta-arrestin-dependent ERK1/2 activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Transduction of Receptor Signals by ß-Arrestins
Lefkowitz, R. J., & Shenoy, S. K. (2005) · Science · doi:10.1126/science.1109237 · Cited by 1,727
Self-citationβ-Arrestin-dependent, G Protein-independent ERK1/2 Activation by the β2 Adrenergic Receptor
Shenoy, S. K., Drake, M. T., Nelson, C. D., Houtz, D. A., Xiao, K., Madabushi, S., Reiter, E., Premont, R. T., Lichtarge, O., & Lefkowitz, R. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506576200 · Cited by 759
Self-citationRegulation of Receptor Trafficking by GRKs and Arrestins
Moore, C. A. C., Milano, S. K., & Benovic, J. L. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.022405.154712 · Cited by 676
GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling
Reiter, E., & Lefkowitz, R. J. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.008 · Cited by 666
Self-citationβ-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7
Rajagopal, S., Kim, J., Ahn, S., Craig, S., Lam, C. M., Gerard, N. P., Gerard, C., & Lefkowitz, R. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912852107 · Cited by 600
Self-citationHunyady, L., & Catt, K. J. (2006) · Molecular Endocrinology · doi:10.1210/me.2004-0536 · Cited by 541
Mitogenic signaling pathways induced by G protein‐coupled receptors
Rozengurt, E. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21246 · Cited by 460
The Diverse Roles of Arrestin Scaffolds in G Protein–Coupled Receptor Signaling
Peterson, Y. K., & Luttrell, L. M. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013367 · Cited by 422
Endosomes: A legitimate platform for the signaling train
Murphy, J. E., Padilla, B. E., Hasdemir, B., Cottrell, G. S., & Bunnett, N. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906541106 · Cited by 373
Heuberger, D. M., & Schuepbach, R. A. (2019) · Thrombosis Journal · doi:10.1186/s12959-019-0194-8 · Cited by 371
Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling
Luttrell, L. M., Gesty-Palmer, D., & Sibley, D. R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002436 · Cited by 369
Structure, function and pathophysiology of protease activated receptors
Adams, M. N., Ramachandran, R., Yau, M.-K., Suen, J. Y., Fairlie, D. P., Hollenberg, M. D., & Hooper, J. D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.003 · Cited by 370
CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration
Décaillot, F. M., Kazmi, M. A., Lin, Y., Ray-Saha, S., Sakmar, T. P., & Sachdev, P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277038 · Cited by 333
Metzemaekers, M., Vanheule, V., Janssens, R., Struyf, S., & Proost, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01970 · Cited by 328
Inhibition of tissue factor signaling suppresses tumor growth
Versteeg, H. H., Schaffner, F., Kerver, M., Petersen, H. H., Ahamed, J., Felding-Habermann, B., Takada, Y., Mueller, B. M., & Ruf, W. (2008) · Blood · doi:10.1182/blood-2007-07-101048 · Cited by 327
New Roles for β-Arrestins in Cell Signaling: Not Just for Seven-Transmembrane Receptors
Lefkowitz, R. J., Rajagopal, K., & Whalen, E. J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.007 · Cited by 301
Self-citationSignal transduction by protease‐activated receptors
Soh, U. J., Dores, M. R., Chen, B., & Trejo, J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00705.x · Cited by 294
Protease-activated receptor 2 signaling in inflammation
Rothmeier, A. S., & Ruf, W. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-011-0289-1 · Cited by 289
Hamilton, S. R., Fard, S. F., Paiwand, F. F., Tolg, C., Veiseh, M., Wang, C., McCarthy, J. B., Bissell, M. J., Koropatnick, J., & Turley, E. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702078200 · Cited by 266
Metadata
- Authors
- Ge, L., Shenoy, S. K., Lefkowitz, R. J., & DeFea, K.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-12
- Volume
- 279
- Issue
- 53
- Pages
- 55419-55424
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2014716705
- Cited by
- 177
- References
- 0
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.